<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 5 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Trebuchet MS";
panose-1:2 11 6 3 2 2 2 2 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.DefaultFontHxMailStyle
{mso-style-name:"Default Font HxMail Style";
font-family:"Arial",sans-serif;
color:windowtext;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
span.org
{mso-style-name:org;}
span.locality
{mso-style-name:locality;}
span.region
{mso-style-name:region;}
span.postal-code
{mso-style-name:postal-code;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style></head><body lang=EN-CA link=blue vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span class=DefaultFontHxMailStyle>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>See below for a number of interesting articles.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Glen<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal>Sent from <a href="https://go.microsoft.com/fwlink/?LinkId=550986">Mail</a> for Windows</p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div style='mso-element:para-border-div;border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal style='border:none;padding:0cm'><b>From: </b><a href="mailto:prostatepedia@naspcc.org">Prostatepedia</a><br><b>Sent: </b>December 10, 2021 11:04 AM<br><b>To: </b><a href="mailto:glen46nor@gmail.com">glen46nor@gmail.com</a><br><b>Subject: </b>Prostatepedia Digest Dec 10</p></div><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:7.5pt 7.5pt 7.5pt 7.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm'></td></tr><tr><td valign=top style='background:white;padding:6.75pt 0cm 0cm 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateHeader><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=1975f98cd1&e=d1cc1ed898"><strong><span style='font-size:18.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:red'>Sign up for Prostatepedia's Free Publications</span></strong></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='border:none;border-bottom:solid #EAEAEA 1.5pt;background:white;padding:0cm 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateBody><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=162 style='width:5.875in;height:1.6875in' id="_x0000_i1033" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/d701134e-9eff-4181-a839-0b935f4b3420.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 4.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=eb5aa379f9&e=d1cc1ed898" title=""" "><span style='text-decoration:none'><img border=0 width=564 height=70 style='width:5.875in;height:.7291in' id="_x0000_i1032" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/04bddc1e-91a8-8613-807a-f6a373b36016.png"></span></a><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=79414e8a4e&e=d1cc1ed898" title=""" "><span style='text-decoration:none'><img border=0 width=564 height=70 style='width:5.875in;height:.7291in' id="_x0000_i1031" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/d97e0be7-2879-235d-4d8b-2f43ae798b27.jpg"></span></a><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=3d3e1dc158&e=d1cc1ed898" title=""" "><span style='text-decoration:none'><img border=0 width=564 height=376 style='width:5.875in;height:3.9166in' id="_x0000_i1030" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/f276f954-e8b1-ccc7-d331-5ff84c537e56.jpg"></span></a><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br></span><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>New Links and Resources.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br> </span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>Darolutamide increasing Overall Survival: Arasens Trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=7078f0e0f7&e=d1cc1ed898"><span style='color:#007C89'>Bayer pads blockbuster case for Nubeqa with phase 3 win in metastatic prostate cancer</span></a><br> <br>Mandating Bone-Protecting Agents (BPA’s) to reduce fractures: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=85b8231768&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis</span></a><br> <br>Decision regret, Focal Therapy in localized disease: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=9ac1be37e6&e=d1cc1ed898"><span style='color:#007C89'>Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.</span></a><br> <br>Yoga and Quality of Life: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=79d0b44e69&e=d1cc1ed898"><span style='color:#007C89'>Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial.</span></a><br> <br>Biparametric vs. Multiparametric MRI: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=22aa62a5e1&e=d1cc1ed898"><span style='color:#007C89'>Clinically Significant Prostate Cancer Detection After A Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.</span></a><br> <br>Strengths and Limitations in PSMA PET: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=860d45ea17&e=d1cc1ed898"><span style='color:#007C89'> Strengths and limitations of PSMA PET: When to use it (and when not to) EMUC21 > News > Strengths and limitations of PSMA PET: When to use it (and when not to)</span></a><br> <br>mCRPC: Health-Related Quality of Life, TALAPRO trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=78c5d60b47&e=d1cc1ed898"><span style='color:#007C89'>O3: Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1</span></a><br> <br>Video: Oral Relogolix for ADT; HERO Trial:<a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=ad30cdbc4f&e=d1cc1ed898"><span style='color:#007C89'> HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane</span></a><br> <br>HERO Phase 3 Trial of Oral Relugolix vs leuprolide: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=3a4db80060&e=d1cc1ed898"><span style='color:#007C89'>AUA 2020: HERO Phase 3 Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, vs. Leuprolide Acetate for Advanced Prostate Cancer</span></a><br> <br>Blood-based Biomarkers in men undergoing biopsy: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=41c194cba6&e=d1cc1ed898"><span style='color:#007C89'>Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy.</span></a><br> <br>Olaparib and Abiraterone in mCRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e9e352e2d3&e=d1cc1ed898"><span style='color:#007C89'>Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.</span></a><br> <br>Gut bacteria may fuel prostate cancer growth: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b22650cc21&e=d1cc1ed898"><span style='color:#007C89'>Gut Bacteria May Fuel Prostate Cancer Growth</span></a><br> <br>Gene-mutated prostate cancer: TALAPRO-3 Trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=23629b956a&e=d1cc1ed898"><span style='color:#007C89'> ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer (mCSPC)</span></a><br> <br>Enzalutamide in Castration-Sensitive Prostate Cancer: ARCHES Trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=9b3d8d2c4f&e=d1cc1ed898"><span style='color:#007C89'>ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC</span></a><br> <br>Video: ARCHES Trial: Radiographic Progression-Free Survival: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=29d691a711&e=d1cc1ed898"><span style='color:#007C89'>Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak</span></a><br> <br>Pylarify is commercially available: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c4d010fe6d&e=d1cc1ed898"><span style='color:#007C89'>Lantheus Announces PYLARIFY AI™ is Now Available</span></a><br> <br>Cell-free DNA and AR-V7 splice variant testing: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6755783f4c&e=d1cc1ed898"><span style='color:#007C89'>Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.</span></a><br> <br>Reducing Decision Regret: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6dc3fe2019&e=d1cc1ed898"><span style='color:#007C89'>Quality of life studies may “reduce treatment decision regret”</span></a><br> <br>Gene-expression profiling in mCSPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=98ebc8fa5e&e=d1cc1ed898"><span style='color:#007C89'>PCa Commentary | Volume 159 – November 2021</span></a><br> <br>Quality of Life with Docetaxel versus Abiraterone: STAMPEDE Trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=2a48af181a&e=d1cc1ed898"><span style='color:#007C89'>Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial</span></a><br> <br>Video: Dr. Karim Fizazi discusses cognitive assessment with darolutamide versus enzalutamide: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=183c01bd72&e=d1cc1ed898"><span style='color:#007C89'>Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial - Karim Fizazi</span></a><br> <br>Effects of USPSTF 2012 and 2018 Guidelines on pathologic outcomes after surgery: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=9f825928f1&e=d1cc1ed898"><span style='color:#007C89'>Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.</span></a><br> <br>Trials in Prostate Cancer: ANZUP Annual Scientific Meeting: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e84d1ef995&e=d1cc1ed898"><span style='color:#007C89'>ANZUP Mini ASM 2021: Trials in Prostate Cancer: From Initial Diagnosis To Salvage Therapy in Localized Disease and Trials in the Metastatic Prostate Cancer Setting</span></a><br> <br>Combination therapy with novel androgen receptor antagonists and statins for CRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f4a87b59c6&e=d1cc1ed898"><span style='color:#007C89'>Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.</span></a><br> <br>177 Lutetium-PSMA-617 versus docetaxel in chemo-naïve patients, in mCRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e4bc97cda1&e=d1cc1ed898"><span style='color:#007C89'>177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial.</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>Reminders.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>The 16<sup>th</sup> Annual Meeting of the National Alliance of State Prostate Cancer Coalitions (NASPCC) will take place on a new date: January 28-30, 2022. Here is the link to a description of the Meeting as well as a DRAFT Agenda on our website <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=0193154892&e=d1cc1ed898"><span style='color:#007C89'>here</span></a>.</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c1f83fd256&e=d1cc1ed898"><span style='color:#007C89'>Please join Cedars Sinai for a Webinar entitled "Lineage Plasticity in Prostate Cancer Treatment Resistance" with Amina Zoubeidi, PhD, Canada Research Chair in Cancer Therapy Resistance on Tuesday, December 14, 2021.</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span lang=EN-US style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020;mso-fareast-language:EN-US'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6d7d3cb328&e=d1cc1ed898"><span style='color:#007C89'>Please join NASPCC for a Webinar entitled “Epigenetic Control of Cancer Immunity” With Leigh Ellis, PhD, Scientific Director of the Center for Urologic Research Excellence and Associate Professor, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center on Thursday, January 12, 2022</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=50e038929f&e=d1cc1ed898"><span style='color:#007C89'>Please join NASPCC for a Webinar entitled “Overview of Prostate Cancer Imaging” With Thomas Hope, MD, Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco on Monday, February 7, 2022.</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'>Prostatepedia is looking for a volunteer proofreader. Have editing experience? Want to give back to your fellow patients? Contact <a href="mailto:jessica@prostatepedia.net?subject=Proofreader%20Volunteering"><span style='color:#007C89'>jessica@prostatepedia.net</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=118008804d&e=d1cc1ed898"><span style='color:#007C89'>Merel Grey, president of NASPCC and Cal Ripken, Jr. Talk Prostate Cancer</span></a> <br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=46783ff44c&e=d1cc1ed898"><span style='color:#007C89'>Jessie Myers-Schecter talks about her father, Snuffy Myers, and what it was like to be the daughter of a prostate cancer patient. </span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=507c81be46&e=d1cc1ed898"><span style='color:#007C89'>NASPCC and CancerCare Online Prostate Cancer Patient Support Group</span></a><br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8269c4a558&e=d1cc1ed898"><span style='color:#007C89'>NASPCC Webinar Recordings Archive</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=436 style='width:5.875in;height:4.5416in' id="_x0000_i1029" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/53731a5c-5b34-46de-a306-157337f67b36.jpg"><o:p></o:p></p></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateFooter><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=4a4240ac00&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1028" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-twitter-48.png" alt=Twitter></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=2a47bcd16d&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1027" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-facebook-48.png" alt=Facebook></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=d3080c4c42&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1026" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-link-48.png" alt=Website></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:7.5pt 13.5pt 18.75pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EEEEEE 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Copyright © 2021 Prostatepedia NASPCC, All rights reserved.</span></em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'> <br>You are receiving this email because you opted in via our website. <br><br><strong><span style='font-family:"Helvetica",sans-serif'>Our mailing address is:</span></strong> </span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=org><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Prostatepedia NASPCC</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>1999 Avenue of the Stars Ste 1100<o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=locality><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Los Angeles</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>, <span class=region>CA</span> <span class=postal-code>90067-4618</span><o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><a href="https://naspcc.us17.list-manage.com/vcard?u=9154133f2e98aca1db87520cb&id=c67ed256e6"><span style='color:#656565'>Add us to your address book</span></a><o:p></o:p></span></p></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><br><br><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal><img border=0 width=1 height=1 style='width:.0104in;height:.0104in' id="_x0000_i1025" src="https://naspcc.us17.list-manage.com/track/open.php?u=9154133f2e98aca1db87520cb&id=ec1e1cf9ca&e=d1cc1ed898"><o:p></o:p></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p></div></body></html>